Moderna, Inc. (MRNA) Upgraded to Outperform at William Blair

Market Context

Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $174.38 with a market capitalization of $11.6B. The stock has gained 571.2% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. William Blair's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Moderna, Inc.

Among the 10 most recent ratings: 2 Buy, 6 Hold, 2 Sell.

Date	Firm	Rating	Price Target
Aug 19, 2026	William Blair	Outperform	N/A
Aug 03, 2026	Citigroup	Neutral	N/A
Jul 21, 2026	Goldman Sachs	Neutral	N/A
Jul 08, 2026	Morgan Stanley	Equal-Weight	N/A
Jul 07, 2026	B of A Securities	Underperform	N/A

Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page